Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI

Podobne zapisy

• Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
  od: Imamura, Fumio, i wsp.
  Wydane: (2020)
• The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
  od: Tamiya, Motohiro, i wsp.
  Wydane: (2021)
• Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
  od: Peng, MuYun, i wsp.
  Wydane: (2020)
• Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
  od: Kejing Tang, i wsp.
  Wydane: (2019-02-01)
• Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
  od: Tang, Kejing, i wsp.
  Wydane: (2018)